APO RESEARCH · REPORT
Opioid-Induced Constipation
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
Product & engineering
Understand the product.
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
Selected research
Industry Research
Opioid-Induced Constipation Industry Research Report 2026
Market perspective
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.
North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.
Read the full market overview
In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.
Report Scope
This report quantifies the global Opioid-Induced Constipation market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Opioid-Induced Constipation Market by Company
Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
Opioid-Induced Constipation Segment by Type
Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Others
Opioid-Induced Constipation Segment by Application
Hospital
Pharmacy
Other
Opioid-Induced Constipation Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid-Induced Constipation market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Opioid-Induced Constipation and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid-Induced Constipation.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Opioid-Induced Constipation manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Opioid-Induced Constipation by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Opioid-Induced Constipation in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Methylnaltrexone Bromide
- Lubiprostone
- Naloxegol
- Others
Applications
- Hospital
- Pharmacy
- Other
Companies covered
- Takeda Pharmaceuticals
- Bayer
- Sanofi
- Mallinckrodt
- Salix (Bausch Health)
- AstraZeneca
- Progenics Pharmaceuticals
- Purdue Pharm
- Nektar Therapeutics
- Daiichi Sankyo
- Prestige
- GSK
- Shionogi
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Opioid-Induced Constipation Market Size (2021-2032)
- 2.2.2 Global Opioid-Induced Constipation Sales (2021-2032)
- 2.2.3 Global Opioid-Induced Constipation Market Average Price (2021-2032)
- 2.3 Opioid-Induced Constipation by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Methylnaltrexone Bromide
- 2.3.3 Lubiprostone
- 2.3.4 Naloxegol
- 2.3.5 Others
- 2.4 Opioid-Induced Constipation by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Pharmacy
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Opioid-Induced Constipation Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Opioid-Induced Constipation Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Opioid-Induced Constipation Revenue of Manufacturers (2021-2026)
- 3.4 Global Opioid-Induced Constipation Average Price by Manufacturers (2021-2026)
- 3.5 Global Opioid-Induced Constipation Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Opioid-Induced Constipation, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Opioid-Induced Constipation, Product Type & Application
- 3.8 Global Manufacturers of Opioid-Induced Constipation, Established Date
- 3.9 Global Opioid-Induced Constipation Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda Pharmaceuticals
- 4.1.1 Takeda Pharmaceuticals Company Information
- 4.1.2 Takeda Pharmaceuticals Business Overview
- 4.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolio
- 4.1.5 Takeda Pharmaceuticals Recent Developments
- 4.2 Bayer
- 4.2.1 Bayer Company Information
- 4.2.2 Bayer Business Overview
- 4.2.3 Bayer Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bayer Opioid-Induced Constipation Product Portfolio
- 4.2.5 Bayer Recent Developments
- 4.3 Sanofi
- 4.3.1 Sanofi Company Information
- 4.3.2 Sanofi Business Overview
- 4.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sanofi Opioid-Induced Constipation Product Portfolio
- 4.3.5 Sanofi Recent Developments
- 4.4 Mallinckrodt
- 4.4.1 Mallinckrodt Company Information
- 4.4.2 Mallinckrodt Business Overview
- 4.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Mallinckrodt Opioid-Induced Constipation Product Portfolio
- 4.4.5 Mallinckrodt Recent Developments
- 4.5 Salix (Bausch Health)
- 4.5.1 Salix (Bausch Health) Company Information
- 4.5.2 Salix (Bausch Health) Business Overview
- 4.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Salix (Bausch Health) Opioid-Induced Constipation Product Portfolio
- 4.5.5 Salix (Bausch Health) Recent Developments
- 4.6 AstraZeneca
- 4.6.1 AstraZeneca Company Information
- 4.6.2 AstraZeneca Business Overview
- 4.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 AstraZeneca Opioid-Induced Constipation Product Portfolio
- 4.6.5 AstraZeneca Recent Developments
- 4.7 Progenics Pharmaceuticals
- 4.7.1 Progenics Pharmaceuticals Company Information
- 4.7.2 Progenics Pharmaceuticals Business Overview
- 4.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolio
- 4.7.5 Progenics Pharmaceuticals Recent Developments
- 4.8 Purdue Pharm
- 4.8.1 Purdue Pharm Company Information
- 4.8.2 Purdue Pharm Business Overview
- 4.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Purdue Pharm Opioid-Induced Constipation Product Portfolio
- 4.8.5 Purdue Pharm Recent Developments
- 4.9 Nektar Therapeutics
- 4.9.1 Nektar Therapeutics Company Information
- 4.9.2 Nektar Therapeutics Business Overview
- 4.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Nektar Therapeutics Opioid-Induced Constipation Product Portfolio
- 4.9.5 Nektar Therapeutics Recent Developments
- 4.10 Daiichi Sankyo
- 4.10.1 Daiichi Sankyo Company Information
- 4.10.2 Daiichi Sankyo Business Overview
- 4.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Daiichi Sankyo Opioid-Induced Constipation Product Portfolio
- 4.10.5 Daiichi Sankyo Recent Developments
- 4.11 Prestige
- 4.11.1 Prestige Company Information
- 4.11.2 Prestige Business Overview
- 4.11.3 Prestige Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Prestige Opioid-Induced Constipation Product Portfolio
- 4.11.5 Prestige Recent Developments
- 4.12 GSK
- 4.12.1 GSK Company Information
- 4.12.2 GSK Business Overview
- 4.12.3 GSK Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 GSK Opioid-Induced Constipation Product Portfolio
- 4.12.5 GSK Recent Developments
- 4.13 Shionogi
- 4.13.1 Shionogi Company Information
- 4.13.2 Shionogi Business Overview
- 4.13.3 Shionogi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Shionogi Opioid-Induced Constipation Product Portfolio
- 4.13.5 Shionogi Recent Developments
5 Global Opioid-Induced Constipation Market Scenario by Region
- 5.1 Global Opioid-Induced Constipation Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Opioid-Induced Constipation Sales by Region: 2021-2032
- 5.2.1 Global Opioid-Induced Constipation Sales by Region: 2021-2026
- 5.2.2 Global Opioid-Induced Constipation Sales by Region: 2027-2032
- 5.3 Global Opioid-Induced Constipation Revenue by Region: 2021-2032
- 5.3.1 Global Opioid-Induced Constipation Revenue by Region: 2021-2026
- 5.3.2 Global Opioid-Induced Constipation Revenue by Region: 2027-2032
- 5.4 North America Opioid-Induced Constipation Market Facts & Figures by Country
- 5.4.1 North America Opioid-Induced Constipation Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Opioid-Induced Constipation Sales by Country (2021-2032)
- 5.4.3 North America Opioid-Induced Constipation Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Opioid-Induced Constipation Market Facts & Figures by Country
- 5.5.1 Europe Opioid-Induced Constipation Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Opioid-Induced Constipation Sales by Country (2021-2032)
- 5.5.3 Europe Opioid-Induced Constipation Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Opioid-Induced Constipation Market Facts & Figures by Country
- 5.6.1 Asia Pacific Opioid-Induced Constipation Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Opioid-Induced Constipation Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Opioid-Induced Constipation Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Opioid-Induced Constipation Market Facts & Figures by Country
- 5.7.1 South America Opioid-Induced Constipation Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Opioid-Induced Constipation Sales by Country (2021-2032)
- 5.7.3 South America Opioid-Induced Constipation Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Opioid-Induced Constipation Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Opioid-Induced Constipation Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Opioid-Induced Constipation Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Opioid-Induced Constipation Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Opioid-Induced Constipation Sales by Type (2021-2032)
- 6.1.1 Global Opioid-Induced Constipation Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Opioid-Induced Constipation Sales Market Share by Type (2021-2032)
- 6.2 Global Opioid-Induced Constipation Revenue by Type (2021-2032)
- 6.2.1 Global Opioid-Induced Constipation Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Opioid-Induced Constipation Revenue Market Share by Type (2021-2032)
- 6.3 Global Opioid-Induced Constipation Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Opioid-Induced Constipation Sales by Application (2021-2032)
- 7.1.1 Global Opioid-Induced Constipation Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Opioid-Induced Constipation Sales Market Share by Application (2021-2032)
- 7.2 Global Opioid-Induced Constipation Revenue by Application (2021-2032)
- 7.2.1 Global Opioid-Induced Constipation Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Opioid-Induced Constipation Revenue Market Share by Application (2021-2032)
- 7.3 Global Opioid-Induced Constipation Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Opioid-Induced Constipation Value Chain Analysis
- 8.1.1 Opioid-Induced Constipation Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Opioid-Induced Constipation Production Mode & Process
- 8.2 Opioid-Induced Constipation Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Opioid-Induced Constipation Distributors
- 8.2.3 Opioid-Induced Constipation Customers
9 Global Opioid-Induced Constipation Analyzing Market Dynamics
- 9.1 Opioid-Induced Constipation Industry Trends
- 9.2 Opioid-Induced Constipation Industry Drivers
- 9.3 Opioid-Induced Constipation Industry Opportunities and Challenges
- 9.4 Opioid-Induced Constipation Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst